Abstract
Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Keywords: Cardiac stem cells, chemotherapy-induced cardiotoxicity, pluripotent stem cells, preclinical models, cardiomyopathy, human embryomic stem cell.
Current Drug Targets
Title:Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Volume: 18 Issue: 6
Author(s): Rosalinda Madonna*, Christian Cadeddu, Martino Deidda, Paolo Spallarossa, Concetta Zito and Giuseppe Mercuro*
Affiliation:
- Dipartimento di Scienze Mediche Mario Aresu, Universita of Cagliari,Italy
- Department of Medical Sciences “Mario Aresu”, University of Cagliari, Cagliari,Italy
Keywords: Cardiac stem cells, chemotherapy-induced cardiotoxicity, pluripotent stem cells, preclinical models, cardiomyopathy, human embryomic stem cell.
Abstract: Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Export Options
About this article
Cite this article as:
Madonna Rosalinda*, Cadeddu Christian, Deidda Martino, Spallarossa Paolo, Zito Concetta and Mercuro Giuseppe *, Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160401125404
DOI https://dx.doi.org/10.2174/1389450117666160401125404 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunologic Considerations in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients
Current Proteomics Stress Echocardiography
Current Pharmaceutical Design Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Medicinal Chemistry of Drugs Used in Diabetic Cardiomyopathy
Current Medicinal Chemistry GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects
Current Pharmaceutical Design Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Does Oral Metoprolol have Any Effect on the Functional Parameters and Perfusion Defects of the Left Ventricle?
Current Medical Imaging Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy PREFACE: Cardiovascular and Hematological Medicine in 2015 - Advances and Insights
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians
Current Diabetes Reviews Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Organoselenium Compounds as Potential Therapeutic and Chemopreventive Agents: A Review
Current Medicinal Chemistry New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging